

Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Triple Class Refractory Multiple Myeloma

Key Stakeholder Organizations

ICER receives input on its reviews from patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for key stakeholders in any of these categories. The following is a list of organizations from which ICER has requested input as well as those that have provided public comments or open input submissions during the review. None of these individuals or organizations are responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- Alliance for Regenerative Medicine
- American Society for Blood and Marrow Transplant
- American Society of Hematology
- American Society for Transplantation and Cellular Therapy
- Amgen, Inc.
- Association of Community Cancer Centers
- Bristol Myers Squibb
- bluebird bio
- Blue Cross Blue Shield Association
- Cancer Support Community
- GlaxoSmithKline
- International Myeloma Foundation
- Johnson & Johnson and Legend Biotech Corp
- Leukemia & Lymphoma Society UK
- Multiple Myeloma Research Foundation
- Myelomacrowd.org
- Oncology Analytics
- Patients for Affordable Drugs
- Sanofi
- United Healthcare